tiprankstipranks
pc:aavan

AAVantgarde Bio

https://www.aavantgarde.com/
A clinical-stage biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases. The company's lead programs target Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B, two severe, inherited retinal diseases with no approved treatments.

Leadership & Board

Current Number of Employees70
Current LinkedIn Followers7,184

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$206M
Total Amount Raised$206M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$141M
Latest Funding Amount$141M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Employee Trend

AAVantgarde Bio had 70 employees as of May 18, 2026. The number of employees increased by 0 (0.00%) week-over-week.
70Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

AAVantgarde Bio had 7,184 followers as of May 18, 2026. The number of followers increased by 34 (0.48%) week-over-week.
7,184Latest Followers Count
34(0.48%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Nov 03, 2025
Series B
$141.00M
Jul 06, 2023
Series A
$65.30M

Investors

Investor Name
Funding Round

Related News and Analysis